DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Nitroglycerin Prevents Radial Artery Occlusion

Information source: National Cardiovascular Center Harapan Kita Hospital Indonesia
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Injury of Radial Artery

Intervention: 500 microgram of Nitroglycerin (Drug); Saline 5 mL (Drug)

Phase: N/A

Status: Completed

Sponsored by: National Cardiovascular Center Harapan Kita Hospital Indonesia

Official(s) and/or principal investigator(s):
Surya Dharma, MD, PhD, Principal Investigator, Affiliation: National Cardiovascular Center Harapan Kita


Trans-radial approach (TRA) has becoming popular and widely adopted over the last decade. However, radial artery occlusion (RAO) continues to be one of the limitation of trans-radial access and potentially limits the radial artery as an access site in the future. Several strategies have been used to decrease the incidence of RAO including the use of anticoagulation, maintenance of patency during hemostasis, or shortening the duration of compression. Currently, there is no data whether vasoactive pharmacological therapy such as nitroglycerin administered intra-arterially at the end of the procedure may reduce the incidence of RAO. It is hypothesized that the addition of nitroglycerin (nitric oxide donor) at the end of a TRA procedure may reduce the incidence of RAO.

Clinical Details

Official title: A Novel Approach to Reduce Radial Artery Occlusion After Trans-Radial Catheterization: Post-Procedural/Pre-Hemostasis Intra-Arterial Nitroglycerin

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention

Primary outcome: Incidence of radial artery occlusion as confirmed by absence of antegrade flow in vascular high resolution ultrasound


Minimum age: 18 Years. Maximum age: 80 Years. Gender(s): Both.


Inclusion Criteria:

- Sequential patients undergoing trans-radial catheterization in the institution will

be consented to be randomized to receive either 500 microgram nitroglycerin (Group A) or a placebo (Group B) administered intra-arterially through the sheath at the end of the procedure. Exclusion Criteria:

- Patients with cardiogenic shock or hemodynamically unstable

- Unable to tolerate nitrates

Locations and Contacts

National Cardiovascular Center Harapan Kita, Jakarta 11420, Indonesia
Additional Information

Starting date: October 2013
Last updated: April 2, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017